Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Proven Pseudomonas aeruginosa infection Clinical criteria: Treatment Phase: Initial treatment Patient must have cystic fibrosis, AND Patient must have been assessed for bronchial hyperresponsiveness as per the TGA-approved Product Information, with a negative test result, AND Patient must be participating in a four week trial of tobramycin inhalation powder and will be assessed for ability to tolerate the dry powder formulation in order to qualify for continued PBS-subsidised therapy. The trial commencement date must be documented in the patient's medical records. Population criteria: Patient must be 6 years of age or older. Treatment criteria: Must be treated by a medical practitioner; OR Must be treated by a nurse practitioner where patient care is being shared with a medical practitioner.
Pseudomonas aeruginosa infection Clinical criteria: Patient must have cystic fibrosis, AND The treatment must be systemic.
“Tobramycin is an aminoglycoside antibiotic produced by Streptomyces tenebrarius. It acts primarily by disrupting protein synthesis, leading to altered cell membrane permeability, progressive disruption of the cell envelope, and eventual cell death.”
“The apparent terminal half-life of tobramycin in serum after inhalation of a single 300mg dose of tobramycin solution was approximately 3 hours in CF patients in both dosage forms.”
Working under the parallel aged-care framework? Aged-care equivalent →
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.